Print

HVTN 117 VAC89220HPX2004

NCT02788045

Trial Details:

II Ongoing
Ad26.Mos.HIV Trivalent,Ad26.Mos4.HIV,gp140 C
RandD/trials/Lists/ClinicalTrialsList
12/1/2017
Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol + Ad26.Mos.2.Env; Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol; Protein gp140 C
Ad26.Mos.HIV vaccine at Week 0 and 12, followed by Ad26.Mos.HIV vaccine + Clade C glycoprotein 140 vaccine containing 250 microgram (mcg) of total protein mixed with adjuvant (aluminum phosphate) at Week 24 and 48